Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014;64(1):9–29.

Article  Google Scholar 

Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol Biology (Clifton N J). 2009;471:469–86.

Article  Google Scholar 

Vicidomini G. Current challenges and future advances in Lung Cancer: Genetics, Instrumental diagnosis and treatment. Cancers 2023, 15 (14).

Ichijo H, Hellman U, Wernstedt C, Gonez LJ, Claesson-Welsh L, Heldin CH, Miyazono K. Molecular cloning and characterization of ficolin, a multimeric protein with fibrinogen- and collagen-like domains. J Biol Chem. 1993;268(19):14505–13.

Article  CAS  PubMed  Google Scholar 

Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. Human M-Ficolin is a secretory protein that activates the lectin complement Pathway1. J Immunol. 2005;175(5):3150–6.

Article  CAS  PubMed  Google Scholar 

Matsushita M, Kuraya M, Hamasaki N, Tsujimura M, Shiraki H, Fujita T. Activation of the lectin complement pathway by H-ficolin (Hakata antigen). J Immunol (Baltimore Md : 1950). 2002;168(7):3502–6.

Article  CAS  Google Scholar 

Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol (Baltimore Md : 1950). 2005;175(5):3150–6.

Article  CAS  Google Scholar 

Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Volanakis JE. The role of complement in innate and adaptive immunity. Curr Top Microbiol Immunol. 2002;266:41–56.

CAS  PubMed  Google Scholar 

Pasqualotto E, Moraes FCA, Chavez MP, Souza MEC, Rodrigues A, Ferreira ROM, Lopes LM, Almeida AM, Fernandes MR, Santos N. PD-1/PD-L1 inhibitors plus Chemotherapy Versus Chemotherapy alone for Resectable Non-small Cell Lung Cancer: a systematic review and Meta-analysis of Randomized controlled trials. Cancers. 2023;15:21.

Article  Google Scholar 

Yang X, Yin R, Xu L, Neoadjuvant. PD-1 blockade in Resectable Lung Cancer. N Engl J Med 2018, 379 (9), e14.

Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, Borghaei H, Ramalingam SS, Brahmer J, Reck M, O’Byrne KJ, Geese WJ, Green G, Chang H, Szustakowski J, Bhagavatheeswaran P, Healey D, Fu Y, Nathan F, Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a high Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093–104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO precision oncology 2017, 2017.

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent, B. G.;, Shmulevich. I., The Immune Landscape of Cancer. Immunity 2018, 48 (4), 812–830.e14.

Yang G, Liang Y, Zheng T, Song R, Wang J, Shi H, Sun B, Xie C, Li Y, Han J, Pan S, Lan Y, Liu X, Zhu M, Wang Y, Liu L. FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signaling. Cancer Lett. 2016;378(2):80–6.

Article  CAS  PubMed  Google Scholar 

Ma D, Liu P, Wen J, Gu Y, Yang Z, Lan J, Fan H, Liu Z, Guo D. FCN3 inhibits the progression of hepatocellular carcinoma by suppressing SBDS-mediated blockade of the p53 pathway. Int J Biol Sci. 2023;19(2):362–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Szala A, Sawicki S, Swierzko AS, Szemraj J, Sniadecki M, Michalski M, Kaluzynski A, Lukasiewicz J, Maciejewska A, Wydra D, Kilpatrick DC, Matsushita M, Cedzynski M. Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours. Cancer Immunol Immunotherapy: CII. 2013;62(8):1411–9.

Article  CAS  PubMed Central  Google Scholar 

Sokołowska A, Świerzko AS, Gajek G, Gołos A, Michalski M, Nowicki M, Szala-Poździej A, Wolska-Washer A, Brzezińska O, Wierzbowska A, Jamroziak K, Kowalski ML, Thiel S, Matsushita M, Jensenius JC, Cedzyński M. Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. Sci Rep. 2020;10(1):10561.

Article  PubMed  PubMed Central  Google Scholar 

Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, Louis DN, Iafrate AJ. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810–7.

Article  CAS  PubMed  Google Scholar 

Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004;3(12):1011–22.

Article  CAS  PubMed  Google Scholar 

Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–80.

Article  CAS  PubMed  Google Scholar 

Héja D, Kocsis A, Dobó J, Szilágyi K, Szász R, Závodszky P, Pál G, Gál P. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc Natl Acad Sci USA. 2012;109(26):10498–503.

Article  PubMed  PubMed Central  Google Scholar 

Matsushita M, Endo Y, Hamasaki N, Fujita T. Activation of the lectin complement pathway by ficolins. Int Immunopharmacol. 2001;1(3):359–63.

Article  CAS  PubMed  Google Scholar 

Endo Y, Matsushita M, Fujita T. Role of ficolin in innate immunity and its molecular basis. Immunobiology. 2007;212(4–5):371–9.

Article  CAS  PubMed  Google Scholar 

Horvath L, Puschmann C, Scheiber A, Martowicz A, Sturm G, Trajanoski Z, Wolf D, Pircher A, Salcher S. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC. Trends cancer 2024.

Zhang P, Liu J, Pei S, Wu D, Xie J, Liu J, Li J. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq. Front Immunol. 2023;14:1189520.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Theoharides TC, Conti P. Mast cells: the JEKYLL and HYDE of tumor growth. Trends Immunol. 2004;25(5):235–41.

Article  CAS  PubMed  Google Scholar 

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, Liu J, Freeman GJ, Brown MA, Wucherpfennig KW, Liu XS. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.

Article  CAS  PubMed  Google Scholar 

Zhao Y, Ma Y, Zang A, Cheng Y, Zhang Y, Wang X, Chen Z, Qu S, He J, Chen C, Jin C, Zhu D, Li Q, Liu X, Su W, Ba Y, Hao Y, Chen J, Zhang G, Qu S, Li Y, Feng W, Yang M, Liu B, Ouyang W, Liang J, Yu Z, Kang X, Xue S, Yang G, Yan W, Yang Y, Liu Z, Peng Y, Fanslow B, Huang X, Zhang L, Zhao H. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors. J Hematol Oncol. 2023;16(1):50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu ZZ, Liu YY, Zhu W, Xiao D, Huang W, Lu SS, Yi H, Zeng T, Feng XP, Yuan L, Qiu JY, Wu D, Wen Q, Zhou JH, Zhuang W, Xiao ZQ. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. J Immunother Cancer 2023, 11 (3).

Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26.

Article  PubMed  PubMed Central  Google Scholar 

Genova C, Dellepiane C, Carrega P, Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S, Croce M. Therapeutic implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Front Immunol. 2021;12:799455.

Article  PubMed  Google Scholar